REPL
Replimune Group, Inc.
There isn't enough reported data to score REPL yet.
REPL Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
REPL's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
REPL PE Valuation
REPL has no meaningful PE right now: it lost money over the past year.
REPL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect REPL's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
REPL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.79 | +$0.67 |
| Q2 2026 | -$3.15 | +$0.09 |
| Q1 2026 | -$3.38 | -$0.31 |
| Q4 2025 | -$3.44 | -$0.37 |
| Q3 2025 | -$3.46 | -$0.41 |
| Q2 2025 | -$3.24 | +$0.03 |
| Q1 2025 | -$3.07 | +$0.17 |
| Q4 2024 | -$3.07 | +$0.08 |
REPL is still losing money, but less than at its worst: $2.79 per share over the past year, against $3.46 at its worst in late 2025.
REPL Quarterly Revenue
REPL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.8M | +$34.8M |
| Q2 2026 | -$75.7M | +$4M |
| Q1 2026 | -$56.2M | -$1.3M |
| Q4 2025 | -$66.1M | -$13.6M |
| Q3 2025 | -$82.6M | -$41.8M |
| Q2 2025 | -$79.8M | -$28.9M |
| Q1 2025 | -$54.9M | -$7M |
| Q4 2024 | -$52.5M | -$3.7M |
REPL has burned cash in almost every quarter: −$246M over the past year, against −$270M the year before.
REPL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.6% | +8.3M shares |
| 1 year | +14% | +13.3M shares |
| 3 years | +58% | +38.6M shares |
| 5 years | +102% | +53.1M shares |
| Available history | +202% | +70.3M shares |
REPL has 105M diluted shares, up 14% from a year ago.
REPL Net Leverage
REPL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
REPL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.2 | Overbought |
| Stochastic | 93.5 | Overbought |
REPL's weekly RSI is 73 (overbought) and its Stochastic is 94 (overbought).
REPL PE vs Healthcare Sector
REPL has no meaningful PE right now: it lost money over the past year.
REPL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.3 | 44% above |
| 20 week MA | $13.7 | 60% above |
| 50 week MA | $9.97 | 120% above |
| 100 week MA | $9.51 | 131% above |
| 200 week MA | $11.6 | 89% above |
REPL has climbed back above all five of its weekly moving averages, and it's now 89% above its 200-week average.
REPL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.5 | $41.9 | +171% |
| 2021 | $41.9 | $28.8 | -31% |
| 2022 | $28.8 | $26.8 | -7.1% |
| 2023 | $26.8 | $8.43 | -69% |
| 2024 | $8.43 | $12.3 | +45% |
| 2025 | $12.3 | $9.96 | -19% |
| 2026 YTD | $9.96 | $22.0 | +121% |
REPL's yearly returns have swung widely, from +171% in 2020 to −69% in 2023. It's up 121% so far in 2026.